William Blair & Company maintains ‘Outperform’ rating on PAREXEL (PRXL)

William Blair & Company has released a research report on biopharmaceutical company PAREXEL International Corporation PRXL. WB reiterated an ‘Outperform’ rating on the stock. PAREXEL declared its quarterly results reporting an EPS of $0.32 which was 2 cents higher than the analysts' expectations and consensus. The revenue of the company stood at $295.3, $4 million below the analysts' expectation. Analysts at William Blair said that the company has posted strong results in last three quarters and maintained the EPS estimate of $1.27.